Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855073 | 1.00 | KMT2A (0.49) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL12297754 | 1.00 | KMT2A (0.49) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL31195699 | 1.00 | KMT2A (0.49) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL30802567 | 1.00 | KMT2A (0.49) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL12568253 | 0.93 | KMT2A (0.46) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL32683646 | 0.92 | KMT2A (0.45) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL18614206 | 0.92 | KMT2A (0.45) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL20338593 | 0.92 | KMT2A (0.45) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL12297763 | 0.91 | MDM2 (0.46) | KMT2AEPHX2ITGB3ITGA2BCASP3 | |
| SCHEMBL25362440 | 0.90 | ITGB3 (0.45) | KMT2AEPHX2ITGB3ITGA2BCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2026-04-30 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023118303-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2023-06-29 | — | — | WO | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-20180186860-A1 | SYNTHETIC APOLIPOPROTEINS, AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR NANOLIPOPROTEIN PARTICLES FORMATION | U.S. DEPARTMENT OF ENERGY | 2018-07-05 | — | — | US | disclosed |
| WO-2016181408-A2 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885EPHX2 3594/4885ITGB3 4849/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885EPHX2 3594/4885ITGB3 4849/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | KMT2A 4757/4885EPHX2 3088/4885ITGB3 4650/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885EPHX2 3594/4885ITGB3 4849/4885 |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | OXTR, CRH, TRHR | KMT2A 3331/4885EPHX2 2906/4885ITGB3 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.